The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 27, 2014
Filed:
Jan. 14, 2011
Nick A. Paras, San Francisco, CA (US);
James Brown, Moorpark, CA (US);
Yuan Cheng, Newbury Park, CA (US);
Stephen A. Hitchcock, Jupiter, FL (US);
Ted Judd, Granada Hills, CA (US);
Patricia Lopez, West Hills, CA (US);
Ana Elena Minatti, Santa Monica, CA (US);
Thomas Nixey, Newbury Park, CA (US);
Timothy Powers, Malibu, CA (US);
Christopher M. Tegley, Thousand Oaks, CA (US);
Qiufen Xue, Newbury Park, CA (US);
Bryant Yang, Simi Valley, CA (US);
Wenge Zhong, Thousand Oaks, CA (US);
Nick A. Paras, San Francisco, CA (US);
James Brown, Moorpark, CA (US);
Yuan Cheng, Newbury Park, CA (US);
Stephen A. Hitchcock, Jupiter, FL (US);
Ted Judd, Granada Hills, CA (US);
Patricia Lopez, West Hills, CA (US);
Ana Elena Minatti, Santa Monica, CA (US);
Thomas Nixey, Newbury Park, CA (US);
Timothy Powers, Malibu, CA (US);
Christopher M. Tegley, Thousand Oaks, CA (US);
Qiufen Xue, Newbury Park, CA (US);
Bryant Yang, Simi Valley, CA (US);
Wenge Zhong, Thousand Oaks, CA (US);
Amgen Inc., Thousand Oaks, CA (US);
Abstract
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein ring A, B, B, B, L, R, R, ring Z, m and n of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula (I), intermediates and processes useful for the preparation of compounds of Formula (I).